Literature DB >> 7511625

Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice.

G R Majeau1, W Meier, B Jimmo, D Kioussis, P S Hochman.   

Abstract

Soluble ligands specific for cell surface molecules involved in APC-T cell interactions can signal cells and modulate immune responses. Recently, we reported that LFA3TIP, a fusion protein comprised of the first LFA-3 extracellular domain fused to the hinge, CH2, and CH3 regions of a human IgG1 inhibits proliferation of human T cells in vitro. We report herein the cell-based mechanism(s) of LFA3TIP in inhibition by studying the effects of structurally altered LFA3-Ig fusion proteins on proliferation of human PBL in vitro and on responses of mice transgenic for human CD2. We show that LFA3TIP inhibition requires expression of both the LFA-3 and CH2 domains of the fusion protein that bind CD2 and Fc gamma RI or Fc gamma RIII, respectively. LFA3TIP forms an intracellular Fc gamma R/CD2 bridge and directs cytolysis of CD2+ cells by freshly drawn human PBL in vitro as well as the non-C-mediated depletion of peripheral T cells of human CD2 transgenic mice. The cell-based mechanism(s) of LFA3TIP inhibition are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511625

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression.

Authors:  D J Lo; T A Weaver; L Stempora; A K Mehta; M L Ford; C P Larsen; A D Kirk
Journal:  Am J Transplant       Date:  2010-11-10       Impact factor: 8.086

2.  Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus.

Authors:  Xian-Xing Xu; Xue Shui; Zhi-Hang Chen; Cheng-Qi Shan; Yu-Nan Hou; Yuan-Guo Cheng
Journal:  Mol Biotechnol       Date:  2009-05-06       Impact factor: 2.695

3.  Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration.

Authors:  Ashay K Vaishnaw; Christopher N TenHoor
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

Review 4.  Advances in immunosuppression for renal transplantation.

Authors:  Antoine Durrbach; Helene Francois; Severine Beaudreuil; Antoine Jacquet; Bernard Charpentier
Journal:  Nat Rev Nephrol       Date:  2010-02-02       Impact factor: 28.314

Review 5.  Cellular targeting in autoimmunity.

Authors:  Jennifer L Rogers; Donald S Serafin; Roman G Timoshchenko; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

6.  A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation.

Authors:  K Yamashita; C R Parish; H S Warren; L C Harrison
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

Review 7.  Novel targeted therapies for eosinophilic disorders.

Authors:  Michael E Wechsler; Patricia C Fulkerson; Bruce S Bochner; Gail M Gauvreau; Gerald J Gleich; Tim Henkel; Roland Kolbeck; Sameer K Mathur; Hector Ortega; Jatin Patel; Calman Prussin; Paolo Renzi; Marc E Rothenberg; Florence Roufosse; Dagmar Simon; Hans-Uwe Simon; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 8.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

Review 9.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

10.  Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.

Authors:  Mayte Suárez-Fariñas; Kejal R Shah; Asifa S Haider; James G Krueger; Michelle A Lowes
Journal:  BMC Dermatol       Date:  2010-02-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.